Why IGI Laboratories (IG) Stock Hit a One-Year High Today

NEW YORK (TheStreet) -- Shares of IGI Laboratories  (IG) surged to a 52-week high of $9.01 on Thursday after the pharmaceutical company announced it had acquired regulatory rights to 18 AstraZeneca  (AZN) drugs.

Seventeen of the drugs acquired were marketed. The acquisition includes 17 injectable drugs and one suppository drug. IMS Health estimates the U.S. market for these drugs is $200 million as of May 2014.

The FDA had approved these drugs as abbreviated new drug applications (ANDAs) or new drug applications (NDAs) before they were discontinued or taken off the market.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 18.19% to $8.81 at 2:47 p.m. More than 4 million shares had changed hands, compared to the average volume of 811,739.

IG Chart IG data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Strong On High Volume: IGI Laboratories (IG)

Strong On High Volume: IGI Laboratories (IG)

Today's Weak On High Volume Stock: IGI Laboratories (IG)

Today's Weak On High Volume Stock: IGI Laboratories (IG)

Trade-Ideas: IGI Laboratories (IG) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: IGI Laboratories (IG) Is Today's Strong On High Relative Volume Stock

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

5 Biotech Stocks Poised for Breakouts

5 Biotech Stocks Poised for Breakouts